Navigation Links
Taking insulin for type 2 diabetes could expose patients to greater risk of health complications
Date:2/4/2013

Examining the UK Clinical Practice Research Datalink (CPRD) - data that characterises about 10% of the UK population - a team of researchers from Cardiff University's School of Medicine looked at the risk of death for patients taking insulin compared with other treatments designed to lower blood glucose levels in people with type 2 diabetes.

The team's epidemiological study found people have greater risk of individual complications associated with diabetes such as heart attack, stroke, eye complications and renal disease when compared with patients treated with alternative glucose-lowering treatments.

"Insulin treatment remains the most longstanding blood-glucose-lowering therapies for people with type 2 diabetes, with its use growing markedly in recent years," according to Professor Craig Currie from Cardiff University's School of Medicine, who led the study.

"However, with new diabetes therapies and treatments emerging there has been a new spotlight on treatments to ensure what the best and safest form of diabetes treatment is.

"By reviewing data from CPRD between 1999 and 2011 we've confirmed there are increased health risks for patients with type 2 diabetes who take insulin to manage their condition," he adds.

The study adds to previous findings which identified potential health risks of insulin in this specific group of people.

Initial concerns were first raised regarding the use of insulin in type 2 diabetes from a population-based study in Canada, which reported a three-fold increase in mortality.

A similar study of people in UK primary care with type 2 diabetes treated with insulin also reported a 50% risk of increased mortality compared with another common treatment regimen.

Professor Currie adds: "Patients currently being treated with insulin should not, under any circumstances, stop taking their medications, and it is important to emphasise that this report related to only type 2 diabetes which typically starts in older people who are overweight.

"Each patient's individual circumstances are different and treatment decisions are managed by their clinician with all of their medical history fully considered.

"The vast majority of people who take insulin will experience no adverse effects and it remains a reliable and common form of treatment worldwide but this study shows that we need to investigate this matter urgently and the drug regulatory authorities should take interest in this issue.

"Anyone who is concerned should speak to their GP first before taking any action on managing their condition."


'/>"/>

Contact: Craig Currie
currie@cardiff.ac.uk
44-029-207-57744
Cardiff University
Source:Eurekalert

Related medicine news :

1. Men taking long-acting chronic pain meds 5xs more likely to have low testosterone levels
2. The US Drug Watchdog Now Urges Young Women Who Suffered a Heart Attack or Blood Clotting After Taking Yaz or Yasmin Birth Control Pills to Contact the Johnson Law Group
3. Eat Too Much While Watching TV? Try Taking Smaller Bites
4. Why good resolutions about taking up a physical activity can be hard to keep
5. Mistaking OCD for ADHD has serious consequences
6. Gen X overtaking baby boomers on obesity
7. Millions May Be Taking Vitamin D Unnecessarily, Analysis Suggests
8. Year of Taking Risky Blood Thinners May Be Unnecessary After Stent Surgery
9. Taking Breaks From Prostate Cancer Hormone Therapy Seems Safe: Study
10. Children taking steroids for asthma are slightly shorter than peers
11. Many Teens Drinking, Taking Drugs During School: Survey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... expanded distribution of the GlycoMark test throughout the Northeast U.S. , GlycoMark ... patients with diabetes. The GlycoMark test provides a clinically proven one- to two-week ...
(Date:4/28/2017)... ... , ... The Radiology Business Management Association (RBMA) is pleased to ... election process has been in place since the RBMA was founded in 1968 with ... succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer ...
(Date:4/28/2017)... ... 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a program of ... team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting ... decide to donate. , “Women’s Hospital at Renaissance has been a collection partner ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... People are ... older people. “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa ... Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... Halo Labs announces the launch of a novel low ... Horizon at PEGS 2017 in Boston ... visible particulate matter in biopharmaceutical samples to enable for ... candidate selection and pre-formulation. Halo Labs is ... Elion Labs for system validation. "We are very ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
Breaking Medicine Technology: